erlotinib (tarceva) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB
Back

Drug Pricing Summary

AUS PBS

$6.4228 - $28.2214

VA FSS

$55.1977 - $277.4663

VA Big4

$66.5577 - $201.3310

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
erlotinib 100 mg (TABLET) $23.0802 AUS PBS generic
  • Tarceva (30)
    		•  Roche Products Pty Ltd
    erlotinib 100 mg (TABLET) $130.6827 VA FSS
  • Erlotinib Hydrochloride (30)
    		•  Golden State Medical Supply, Inc.
    erlotinib 100 mg (TABLET) $133.3397 VA FSS
  • Erlotinib (30)
    		•  AvKare, LLC
    erlotinib 100 mg (TABLET) $180.2363 VA Big4
  • TARCEVA (30)
    		•  Genentech USA
    erlotinib 100 mg (TABLET) $245.3127 VA FSS
  • TARCEVA (30)
    		•  Genentech USA
    erlotinib 150 mg (TABLET) $28.2214 AUS PBS generic
  • Tarceva (30)
    		•  Roche Products Pty Ltd
    erlotinib 150 mg (TABLET) $148.3673 VA FSS
  • Erlotinib Hydrochloride (30)
    		•  Golden State Medical Supply, Inc.
    erlotinib 150 mg (TABLET) $150.6270 VA FSS
  • Erlotinib (30)
    		•  AvKare, LLC
    erlotinib 150 mg (TABLET) $201.3310 VA Big4
  • TARCEVA (30)
    		•  Genentech USA
    erlotinib 150 mg (TABLET) $277.4663 VA FSS
  • TARCEVA (30)
    		•  Genentech USA
    erlotinib 25 mg (TABLET) $6.4228 AUS PBS generic
  • Tarceva (30)
    		•  Roche Products Pty Ltd
    erlotinib 25 mg (TABLET) $55.1977 VA FSS
  • Erlotinib Hydrochloride (30)
    		•  Golden State Medical Supply, Inc.
    erlotinib 25 mg (TABLET) $66.5577 VA Big4
  • TARCEVA (30)
    		•  Genentech USA
    erlotinib 25 mg (TABLET) $89.3127 VA FSS
  • TARCEVA (30)
    		•  Genentech USA

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue